GlaxoSmithKline plc (GSKN) — Free Cash Flow Generation Index
GlaxoSmithKline plc (GSKN) has a Free Cash Flow Generation Index of 0.60x as of September 2025. Free cash flow of MX$1.34 Billion represents 1% of operating cash flow (MX$2.22 Billion). Read GSKN current and long-term liabilities for a breakdown of total debt and financial obligations.
FCF Generation Index
Free Cash Flow
Operating Cash Flow
Capital Expenditures
GlaxoSmithKline plc Free Cash Flow Generation Index (2013–2024)
Historical FCF Generation Index trend for GlaxoSmithKline plc across 12 annual periods. Explore GlaxoSmithKline plc capex to cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Annual Free Cash Flow Generation for GlaxoSmithKline plc (2013–2024)
Year-by-year Free Cash Flow Generation Index for GlaxoSmithKline plc. For the full company profile including market capitalisation, see GlaxoSmithKline plc stock valuation.
| Year | FCG Index | Free Cash Flow (MXN) | Operating CF | Capital Expenditures | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.55x | MX$3.57 Billion | MX$6.55 Billion | MX$2.98 Billion | ▼ -5.7% |
| 2023 | 0.58x | MX$3.17 Billion | MX$5.48 Billion | MX$2.31 Billion | ▼ -16.9% |
| 2022 | 0.69x | MX$5.14 Billion | MX$7.40 Billion | MX$1.14 Billion | ▲ +10.1% |
| 2021 | 0.63x | MX$5.02 Billion | MX$7.95 Billion | MX$950.00 Million | ▼ -14.1% |
| 2020 | 0.73x | MX$6.20 Billion | MX$8.44 Billion | MX$989.00 Million | ▲ +0.6% |
| 2019 | 0.73x | MX$5.86 Billion | MX$8.02 Billion | MX$1.26 Billion | ▼ -7.2% |
| 2018 | 0.79x | MX$6.62 Billion | MX$8.42 Billion | MX$1.34 Billion | ▲ +15.4% |
| 2017 | 0.68x | MX$4.72 Billion | MX$6.92 Billion | MX$1.54 Billion | ▼ -49.9% |
| 2016 | 1.36x | MX$8.85 Billion | MX$6.50 Billion | MX$2.35 Billion | ▼ -11.4% |
| 2015 | 1.54x | MX$3.95 Billion | MX$2.57 Billion | MX$1.38 Billion | ▲ +25.0% |
| 2014 | 1.23x | MX$6.36 Billion | MX$5.18 Billion | MX$1.19 Billion | ▲ +5.6% |
| 2013 | 1.16x | MX$8.41 Billion | MX$7.22 Billion | MX$1.19 Billion | — |